Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Nelson Van Denburg & Campbell Wealth Management Group LLC

Posted by on Jun 13th, 2023

Nelson Van Denburg & Campbell Wealth Management Group LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 17.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,024 shares of the biopharmaceutical company’s stock after selling 217 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Regeneron Pharmaceuticals were worth $739,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Joel Isaacson & Co. LLC increased its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Joel Isaacson & Co. LLC now owns 3,253 shares of the biopharmaceutical company’s stock valued at $2,347,000 after purchasing an additional 14 shares in the last quarter. Quent Capital LLC grew its holdings in shares of Regeneron Pharmaceuticals by 4.9% during the fourth quarter. Quent Capital LLC now owns 323 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 15 shares in the last quarter. Colonial River Wealth Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 4.6% during the fourth quarter. Colonial River Wealth Management LLC now owns 341 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 15 shares in the last quarter. JSF Financial LLC grew its holdings in shares of Regeneron Pharmaceuticals by 2.5% during the fourth quarter. JSF Financial LLC now owns 702 shares of the biopharmaceutical company’s stock worth $506,000 after buying an additional 17 shares in the last quarter. Finally, Plancorp LLC grew its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the first quarter. Plancorp LLC now owns 2,276 shares of the biopharmaceutical company’s stock worth $1,590,000 after buying an additional 17 shares in the last quarter. 84.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Jefferies Financial Group upped their target price on shares of Regeneron Pharmaceuticals from $925.00 to $940.00 in a report on Thursday, March 30th. SVB Leerink raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, March 27th. Royal Bank of Canada upped their target price on shares of Regeneron Pharmaceuticals from $811.00 to $816.00 in a report on Friday. Barclays upped their target price on shares of Regeneron Pharmaceuticals from $815.00 to $915.00 and gave the stock an “overweight” rating in a report on Friday, March 24th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, March 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $854.74.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider George Yancopoulos sold 3,656 shares of the stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $804.26, for a total value of $2,940,374.56. Following the transaction, the insider now directly owns 196,848 shares in the company, valued at $158,316,972.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $735.42, for a total value of $73,542.00. Following the completion of the sale, the director now directly owns 18,847 shares of the company’s stock, valued at $13,860,460.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider George Yancopoulos sold 3,656 shares of the stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $804.26, for a total value of $2,940,374.56. Following the completion of the sale, the insider now directly owns 196,848 shares of the company’s stock, valued at $158,316,972.48. The disclosure for this sale can be found here. Insiders have sold 11,891 shares of company stock worth $9,564,150 over the last three months. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.0 %

REGN stock opened at $754.01 on Tuesday. The company’s 50 day moving average price is $773.56 and its 200 day moving average price is $758.26. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.67 and a current ratio of 5.45. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $538.01 and a fifty-two week high of $837.55. The firm has a market capitalization of $82.44 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 2.39 and a beta of 0.23.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $8.44 EPS for the quarter, beating the consensus estimate of $7.71 by $0.73. The company had revenue of $3.16 billion for the quarter, compared to analyst estimates of $2.92 billion. Regeneron Pharmaceuticals had a net margin of 33.81% and a return on equity of 20.41%. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 34.76 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

See Also

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.